Acalabrutinib OverviewAcalabrutinib (Calquence, rINN, ACP-196) is a novel anti-cancer drug and a second generation Bruton's tyrosine kinase (BTK) inhibitor developed by Acerta Pharma. It is more potent and selective (fewer side-effects) than ibrutinib, the first-in-class BTK inhibitor. In October 2017, the Food and Drug Administration approved the drug for treatment of mantle cell l...
Read more Acalabrutinib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Acalabrutinib
Recent Acalabrutinib Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Capsule: 100mg
Other drugs which contain Acalabrutinib or a similar ingredient: (1 result)
- CALQUENCE Acalabrutinib